
Skill Title
Design, validate, and troubleshoot immunogenicity assays for biopharmaceuticals
What You Can Do
You'll design robust immunogenicity assay protocols from conception through regulatory submission, select optimal assay platforms (ELISA, MSD/ECL, SPR, cell-based), troubleshoot protocol failures rapidly, and generate defensible validation documentation compliant with ICH E14 and FDA/EMA expectations. This skill eliminates costly early-stage assay failures and accelerates your path to clinically deployable immunogenicity testing strategies.
Features
choose between ELISA, MSD/ECL, BIAcore/SPR, cell-based, and luciferase immunoprecipitation systems based on your therapeutic modality
structured workflows for assay development from concept to validation plan
ensure selectivity, sensitivity, accuracy, precision, linearity, and reproducibility meet regulatory standards
diagnose high background, poor signal-to-noise, inconsistent recovery, and false positive failures
tier assay approaches (screening, confirmatory, characterization) aligned with development stage
contextualize ADA prevalence, titers, neutralizing vs. binding antibodies, and kinetic profiles
prepare submissions with scientifically justified assay rationale and validation evidence
learn from industry failures in immunogenicity assay development
Example Output
Example 1: Assay Platform Recommendation
- For a PEGylated fusion protein, recommend MSD/ECL platform over ELISA due to lower background in presence of PEG, superior multiplexing capability for binding vs. neutralizing antibody differentiation, and faster turnaround for large clinical cohorts
Example 2: Validation Troubleshooting
- Identify root cause of 40% signal loss post-shipping as osmotic stress on immobilized antigen; recommend buffer reformulation, validation of stability post-shipment, and revised standard operating procedures
Example 3: Regulatory-Ready Documentation
- Generates ICH E14-compliant validation summary report with accuracy ranges by analyte concentration, precision tables (intra/inter-assay), reproducibility across three operators/lots, and justified acceptance criteria with predefined cutoff strategies
What's Included
- SKILL.md: complete immunogenicity assay design and troubleshooting instruction set
- Assay Platform Selection Matrix: decision framework comparing ELISA, MSD/ECL, SPR, cell-based, and LIPS platforms
- ICH E14 Validation Checklist: parameter-by-parameter validation requirements with acceptance criteria templates
- Troubleshooting Decision Tree: flowchart for diagnosing common assay failures with remediation strategies
- Clinical Immunogenicity Testing Strategy Template: tier design (screening, confirmatory, characterization) with statistical power recommendations
- Regulatory Submission Package Outline: documentation structure for FDA/EMA submissions with key evidence tables
Who It's For
- Bioanalytical Scientists developing and validating immunogenicity assays for biopharmaceutical programs
- Immunogenicity Specialists supporting clinical trial design and data interpretation
- Analytical Method Development Leads responsible for assay platform selection and protocol optimization
- Regulatory Affairs Scientists preparing immunogenicity sections for IND/BLA submissions
- Program Managers overseeing immunogenicity strategy and timelines for antibody and protein therapeutics
Best For
- Anti-drug antibody (ADA) assay protocol design from concept through validation for regulatory filing
- Assay platform evaluation and selection for monoclonal antibodies, fusion proteins, bispecifics, and cell therapies
- Method validation troubleshooting — diagnosing and resolving assay failures before regulatory submission
- Clinical immunogenicity testing strategy — designing tiered assay approaches aligned with development stage and MOA
- Regulatory documentation preparation — generating ICH E14-compliant validation reports for FDA/EMA submissions







